Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions

被引:20
作者
Graziani, Gina M. [1 ]
Angel, Jonathan B. [1 ,2 ]
机构
[1] Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada
[2] Ottawa Gen Hosp, Div Infect Dis, Ottawa, ON K1H 8L6, Canada
关键词
HIV; AIDS; analytical treatment interruption(s); clinical trials; outcome measure; therapeutic vaccine; vaccine efficacy; viral reservoir; T-CELL RESPONSES; STRUCTURED TREATMENT INTERRUPTION; ACTIVE ANTIRETROVIRAL THERAPY; HEPATITIS-B PATIENTS; PHASE-II TRIAL; CLINICAL-TRIALS; HIV-1-INFECTED PATIENTS; DOUBLE-BLIND; ALVAC-HIV; IMMUNOLOGICAL RESPONSE;
D O I
10.7448/IAS.18.1.20497
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: The development of an effective therapeutic HIV vaccine that induces immunologic control of viral replication, thereby eliminating or reducing the need for antiretroviral therapy (ART), would be of great value. Besides the obvious challenges of developing a therapeutic vaccine that would generate effective, sustained anti-HIV immunity in infected individuals is the issue of how to best assess the efficacy of vaccine candidates. Discussion: This review discusses the various outcome measures assessed in therapeutic HIV vaccine clinical trials involving individuals receiving suppressive ART, with a particular focus on the role of analytical treatment interruption (ATI) as a way to assess the virologic control induced by an immunotherapy. This strategy is critical given that there are otherwise no readily available measures to determine the ability of a vaccine-induced immune response to effectively control HIV replication. The various outcome measures that have been used to assess vaccine efficacy in published therapeutic HIV vaccine clinical trials will also be discussed. Outcome measures have included the kinetics of viral rebound, the new viral set point and changes in the size of the viral reservoir. Clinically relevant outcomes such as the CD4 decline, the time to resume therapy or the time to meet the criterion to resume therapy, the proportion of participants who resume therapy and/or the development of clinical symptoms such as acute retroviral syndrome are also measures of vaccine efficacy. Conclusions: Given the lack of consistency between therapeutic HIV vaccine trials in how efficacy is assessed, comparing vaccines has been difficult. It would, therefore, be beneficial to determine the most clinically relevant measure for use in future studies. Other recommendations for future clinical trials also include studying compartments in addition to blood and replacing ATIs with single-copy assays in situations in which the use of an ATI is not ideal.
引用
收藏
页数:16
相关论文
共 131 条
[91]   Zoster Vaccine: Current Status and Future Prospects [J].
Oxman, Michael N. .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (02) :197-213
[92]   A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults [J].
Oxman, MN ;
Levin, MJ ;
Johnson, GR ;
Schmader, KE ;
Straus, SE ;
Gelb, LD ;
Arbeit, RD ;
Simberkoff, MS ;
Gershon, AA ;
Davis, LE ;
Weinberg, A ;
Boardman, KD ;
Williams, HM ;
Zhang, JHY ;
Peduzzi, PN ;
Beisel, CE ;
Morrison, VA ;
Guatelli, JC ;
Brooks, PA ;
Kauffman, CA ;
Pachucki, CT ;
Neuzil, KM ;
Betts, RF ;
Wright, PF ;
Griffin, MR ;
Brunell, P ;
Soto, NE ;
Marques, AR ;
Keay, SK ;
Goodman, RP ;
Cotton, DJ ;
Gnann, JW ;
Loutit, J ;
Holodniy, M ;
Keitel, WA ;
Crawford, GE ;
Yeh, SS ;
Lobo, Z ;
Toney, JF ;
Greenberg, RN ;
Keller, PM ;
Harbecke, R ;
Hayward, AR ;
Irwin, MR ;
Kyriakides, TC ;
Chan, CY ;
Chan, ISF ;
Wang, WWB ;
Annunziato, PW ;
Silber, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2271-2284
[93]   A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals [J].
Palefsky, Joel M. ;
Berry, J. Michael ;
Jay, Naomi ;
Krogstad, Marya ;
Da Costa, Maria ;
Darragh, Teresa M. ;
Lee, Jeannette Y. .
AIDS, 2006, 20 (08) :1151-1155
[94]   Vaccine and immunotherapeutic interventions [J].
Pantaleo, Giuseppe ;
Levy, Yves .
CURRENT OPINION IN HIV AND AIDS, 2013, 8 (03) :236-242
[95]   Treatment interruption strategies: how great are the risks? [J].
Paton, Nicholas I. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2008, 21 (01) :25-30
[96]   Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen [J].
Patterson, BK ;
Carlo, DJ ;
Kaplan, MH ;
Marecki, M ;
Pawha, S ;
Moss, RB .
AIDS, 1999, 13 (13) :1607-1611
[97]   Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir [J].
Persaud, Deborah ;
Luzuriaga, Katherine ;
Ziemniak, Carrie ;
Muresan, Petronella ;
Greenough, Thomas ;
Fenton, Terry ;
Blackford, Amanda ;
Ferguson, Kimberly ;
Neu, Natalie ;
Cunningham, Coleen K. .
AIDS, 2011, 25 (18) :2227-2234
[98]   A High HIV DNA Level in PBMCs at Antiretroviral Treatment Interruption Predicts a Shorter Time to Treatment Resumption, Independently of the CD4 Nadir [J].
Piketty, Christophe ;
Weiss, Laurence ;
Assoumou, Lambert ;
Burgard, Marianne ;
Melard, Aurelie ;
Ragnaud, Jean-Michel ;
Bentata, Michele ;
Girard, Pierre-Marie ;
Rouzioux, Christine ;
Costagliola, Dominique .
JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (11) :1819-1828
[99]   Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial [J].
Pollard, Richard B. ;
Rockstroh, Jurgen K. ;
Pantaleo, Giuseppe ;
Asmuth, David M. ;
Peters, Barry ;
Lazzarin, Adriano ;
Garcia, Felipe ;
Ellefsen, Kim ;
Podzamczer, Daniel ;
van Lunzen, Jan ;
Arasteh, Keikawus ;
Schuermann, Dirk ;
Clotet, Bonaventura ;
Hardy, W. David ;
Mitsuyasu, Ronald ;
Moyle, Graeme ;
Plettenberg, Andreas ;
Fisher, Martin ;
Fatkenheuer, Gerd ;
Fischl, Margaret ;
Taiwo, Babafemi ;
Baksaas, Ingebjorg ;
Jolliffe, Darren ;
Persson, Stefan ;
Jelmert, Oyvind ;
Hovden, Arnt-Ove ;
Sommerfelt, Maja A. ;
Wendel-Hansen, Vidar ;
Sorensen, Birger .
LANCET INFECTIOUS DISEASES, 2014, 14 (04) :291-300
[100]  
Radulovic S, 2009, J BUON, V14, pS165